Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Merck (MSD) has collaborated with contract research services company IRBM for the identification and development of new peptide therapeutics that can target various strains of coronavirus, including SARS-CoV-2.
The alliance will work on hit to lead optimisation and preclinical development to rapidly advance therapeutic candidates into the clinic.
IRBM is involved in peptide drug development, including target validation, initial hit identification and the development of a clinical candidate, established in 2010 as a spin-off from MSD.